Gossamer Bio adds Greg Ciongoli to board and audit committee
The seralutinib developer named the Adiumentum Capital founder as a Class III director effective September 16, 2026.
SEC filing
Latest
6 stories
Wednesday, September 16
Friday, September 4
Gossamer Bio files Form D for $150 million offering of rights to acquire securities
The San Diego biotechnology company reported $25 million sold so far to 38 investors, with $125 million remaining under the notice.
SEC filing
Friday, August 21
Gossamer Bio secures up to $250 million private placement tied to seralutinib milestones
The deal funds $150 million in committed capital plus warrants worth up to $100 million more if seralutinib wins FDA approval in PAH.
SEC filing
Thursday, August 13
Gossamer reports Q2 2026 results, reacquires seralutinib rights from Chiesi
Gossamer says it remains on track to file its seralutinib NDA in PAH in September 2026 after a Pre-NDA meeting with the FDA, while reporting $57.0 million in cash as of June 30, 2026.
SEC filing
Monday, July 27
Gossamer Bio reacquires worldwide seralutinib rights from Chiesi, targets September NDA
Gossamer said an FDA Pre-NDA meeting supports filing seralutinib for PAH in September 2026, after ending its collaboration with Chiesi.
SEC filing
Tuesday, July 14
Gossamer Bio stockholders approve charter amendment, incentive plan changes
At a July 14, 2026 special meeting, shareholders backed a share increase to 4 billion, a restated incentive plan, and authority for a reverse stock split tied to the company's debt exchange.
SEC filing